MINI FUTURE SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 17:15:58 28/06/2024 BST | After market 20:17:41 | |||
| 3.5 EUR | -0.85% |
|
3.535 | +1.00% |
| Current month | -0.56% | ||
| 1 month | +1.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 3.5 | -0.85% |
| 27/06/24 | 3.53 | +2.62% |
| 26/06/24 | 3.44 | -0.86% |
| 25/06/24 | 3.47 | +0.29% |
| 24/06/24 | 3.46 | -1.70% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 05:15 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB3LJ3 |
| ISIN | DE000MB3LJ35 |
| Date issued | 13/02/2023 |
| Strike | 79.36 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.65 € |
|---|---|
| Lowest since issue | 0.74 € |
| Spread | 0.01 € |
| Spread % | 0.28% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51
USD
Average target price
53.19
USD
Spread / Average Target
+28.15%
- Stock Market
- Certificates
- Certificat
